Welcome to our dedicated page for iRhythm Holdings SEC filings (Ticker: IRTC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
iRhythm Holdings, Inc. filings document the public-company reporting of a digital health care business centered on ambulatory cardiac monitoring. Recent Form 8-K disclosures report operating results, financial condition, guidance-related exhibits, Regulation FD materials, material agreements, executive compensation policy changes, board appointments, and changes in the independent registered public accounting firm.
Proxy materials cover director elections, board and committee structure, executive compensation, equity awards, and stockholder voting matters. The filing record also documents the completed holding-company reorganization under which iRhythm Holdings became successor registrant to iRhythm Technologies, including common-stock continuity and predecessor registration-termination records.
Mervin Smith reported proposed sales of Common Stock tied to performance shares. The filing lists 2,585 performance shares with a transaction date of 02/24/2026 and identifies the broker Morgan Stanley Smith Barney LLC.
The filing also records prior sales by Mervin Smith during the past three months: 1,352 shares on 03/02/2026 for $173,652.33, 4,041 shares on 02/25/2026 for $547,227.77, and 732 shares on 02/24/2026 for $103,146.12.
iRhythm Holdings, Inc. appointed Jason Patten to its Board of Directors and Audit Committee, effective March 12, 2026, with a term running until the 2026 annual stockholder meeting. The Board determined he qualifies as an independent director and meets SEC Rule 10A-3 audit committee standards and Nasdaq listing requirements.
Under the non-employee Director Compensation Policy, Patten received an initial restricted stock unit grant with a grant date value of $300,000, vesting annually over three years following March 12, 2026, and accelerating upon a change of control if he remains in service. He will also receive an annual cash retainer of $55,000 for Board service and $10,000 for Audit Committee service, paid quarterly. Before joining the Board, he advised the CEO and was paid $86,771 in cash for that role.
iRhythm Holdings, Inc. reported that executive officer Minang Turakhia, its chief medical and scientific officer, executed open-market sales of a total of 4,027 shares of common stock on March 2, 2026 at prices around $128.45 per share. According to the footnote, these shares were sold specifically to cover tax withholding and remittance obligations arising from the vesting of restricted stock units. Following these transactions, Turakhia directly holds 54,906 shares of iRhythm common stock.
iRhythm Holdings, Inc. executive Sumi Shrishrimal, EVP and Chief Risk Officer, reported selling a total of 2,830 shares of common stock in three open-market transactions on March 2, 2026 at prices around $128.44 per share. According to the disclosure, these shares were sold to cover tax withholding and remittance obligations related to the vesting of Restricted Stock Units (RSUs). Following these sales, Shrishrimal directly owned 41,870 shares of iRhythm common stock.
iRhythm Holdings, Inc. executive vice president of strategic business operations Mervin Smith reported selling 1,352 shares of common stock on March 2, 2026 in open‑market transactions at prices around $128.44 per share. The filing states the shares were sold to cover tax withholding obligations from vesting restricted stock units, and Smith held 25,612 shares afterward.
iRhythm Holdings, Inc. executive Chad Patterson, the Chief Commercial & Product Officer, reported open-market sales totaling 4,444 shares of common stock on March 2, 2026, at prices around $128.44 per share.
According to the footnote, these shares were sold to cover tax withholding and remittance obligations tied to vesting Restricted Stock Units, and Patterson continues to hold 58,164 shares directly.
iRhythm Holdings, Inc. executive Patrick Michael Murphy, the company’s CBO and CLO, reported selling 4,357 shares of common stock on March 2, 2026. The shares were sold in several open-market transactions at prices around $128.44 per share to satisfy tax withholding and remittance obligations tied to the vesting of Restricted Stock Units. After these transactions, he continued to hold 63,203 shares of iRhythm common stock.
iRhythm Holdings, Inc. Chief Accounting Officer Marc Wade Rosenbaum reported two small sales of common stock related to equity compensation. On March 2, 2026, he sold 399 shares at $128.447 per share and 417 shares at $128.452 per share. A footnote states these sales were made to cover tax withholding and remittance obligations tied to vesting Restricted Stock Units, rather than discretionary selling. After these transactions, he directly held 16,706 shares of iRhythm common stock.
iRhythm Holdings, Inc. Chief Financial Officer Daniel G. Wilson reported open-market sales of company common stock primarily for tax withholding. On March 2, 2026, he sold a total of 3,395 shares of common stock in several open-market transactions at prices around $128.44 per share to cover tax withholding and remittance obligations related to vesting Restricted Stock Units.
After these sales, Wilson directly owned 35,660 shares of iRhythm common stock and indirectly held 100 shares through The Wilson Living Trust dated July 9, 2015, of which he is the trustee.
iRhythm Holdings, Inc. President and CEO Quentin S. Blackford reported selling a total of 13,813 shares of common stock on March 2, 2026 at prices around $128.44 per share. According to the filing, these shares were sold to cover tax withholding obligations tied to vesting restricted stock units. After these transactions, he directly owned 204,155 shares of iRhythm common stock.